Abstract 1788
Background
PET/CT is an essential component in the initial assessment of locally advanced NSCLC. However, the role of PET/CT in the assessment of response to therapies is not well established.
Methods
We reviewed all stage III NSCLC patients assessed at our centre between January 2009 and March 2018, selecting those with PET/CT evaluation at diagnosis and after treatment (chemotherapy and/or radiotherapy). We evaluated the prognostic differences between mayor PET/CT response (reduction of ≥ 50% of initial SUVmax), minor PET response (reduction of < 50%) and absence of response, by Cox regression. We assessed the predictive value of PET/CT for pathological response in both tumour and mediastinal nodes in patients who had undergone surgery after an induction treatment.
Results
We reviewed 249 patients. In 92,3% an initial PET/CT evaluation was carried out. 117 patients (46.9%) had a PET/CT re-evaluation after an initial chemotherapy and/or radiotherapy treatment. We observed a higher risk of disease progression in patients with a minor PET/CT response (HR 1.97; IC95% 1.2-3.2) and without a response (HR 2.3; IC95% 1.4-4.6, p < 0.01). Progression free survival (PFS) at 12 months was 73%, 47% and 32% among patients with a mayor response, a minor response and no response, respectively. Differences in overall survival (OS) did not reach statistical significance (p = 0,06), but a higher risk for death was seen with a minor response (HR 1.7; IC95%, 1-2,9) and no response (HR 2.1; IC95%, 1,2-3,9). 37 patients (14.9%) underwent surgery after an induction treatment. A greater reduction of SUVmax was observed when pathological response was achieved (mean SUVmax reduction of 94% with complete pathological response vs 27% in absence of response). 22 patients with N2 disease pre-induction therapy underwent surgery. SUVmax reduction was higher in patients with a response (60% vs 35%). However, post-induction mediastinal SUVmax > 2.5 presented a sensitivity of only 42.9% and a specificity of 87.5%.
Conclusions
PET/CT response after induction therapy was a good prognosticator for PFS and OS in stage III NSCLC patients. However, response evaluation by PET/CT should be interpreted with caution due to its lack of precision.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Calvo de Juan: Honoraria (self): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self): Boerhinger; Honoraria (self): Roche. M. Provencio: Honoraria (self), Research grant / Funding (institution): BMS; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boerhinger. All other authors have declared no conflicts of interest.
Resources from the same session
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract